The impact of the gut microbiota on drug metabolism and clinical outcome

Yale Journal of Biology and Medicine

Volumn 89, Issue 3, 2016, Pages 375-382

  Enright, Elaine F ^a,b   Gahan, Cormac G M ^a,b   Joyce, Susan A ^a,b   Griffin, Brendan T ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Drug metabolism; Gastrointestinal; Microbiome; Microbiota; Pharmacokinetics

Indexed keywords

AMIODARONE; CALCITONIN; CYCLOPHOSPHAMIDE; DICLOFENAC; DIGOXIN; GEMCITABINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDOMETACIN; INSULIN; IPILIMUMAB; IRINOTECAN; KETOPROFEN; LEVODOPA; LOPERAMIDE 1 OXIDE; METRONIDAZOLE; MEVINOLIN; NITRAZEPAM; NIZATIDINE; OLANZAPINE; OLSALAZINE; PARACETAMOL; PROBIOTIC AGENT; PRODRUG; RANITIDINE; RISPERIDONE; SALAZOSULFAPYRIDINE; SULFAMIDOCHRYSOIDINE; TACROLIMUS; UNINDEXED DRUG; ZONISAMIDE;

ATRIAL FIBRILLATION; BIFIDOBACTERIUM; CANCER CHEMOTHERAPY; CLINICAL OUTCOME; CONGESTIVE HEART FAILURE; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG TRANSFORMATION; DYSLIPIDEMIA; ENTEROHEPATIC CIRCULATION; GASTROINTESTINAL TOXICITY; GRAFT REJECTION; HELICOBACTER PYLORI; HUMAN; INTESTINE FLORA; LIVER TOXICITY; METABOLOMICS; MICROBIAL METABOLISM; NONHUMAN; PARKINSON DISEASE; REVIEW; SIDE EFFECT; ULCERATIVE COLITIS; WEIGHT GAIN; GASTROINTESTINAL TRACT; MICROBIOLOGY; MICROFLORA; PHARMACOKINETICS; PHYSIOLOGY;

GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT; HUMANS; MICROBIOTA; PHARMACOKINETICS;

EID: 84989352643     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Bäckhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon Ji. Host-Bacterial Mutualism in the Human intestine. Science. 2005;307(5717):1915-20.
2. Marchesi JR, Ravel J. The vocabulary of microbiome research: a proposal. Microbiome. 2015;3:31.
3. Scarpellini E, ianiro G, Attili F, Bassanelli C, De Santis A, Gasbarrini A. The human gut microbiota and virome: Potential therapeutic implications. Digestive and Liver Disease. 2015;47(12):1007-1012.
4. Voigt RM, Forsyth CB, Green SJ, Mutlu E, Engen P, Vita-terna MH, et al. Circadian Disorganization Alters intestinal Microbiota. PloS One. 2014;9(5):e97500.
5. Sousa T, Paterson R, Moore V, Carlsson A, Abrahamsson B, Basit AW. The gastrointestinal microbiota as a site for the biotransformation of drugs. int J Pharm. 2008;363(1-2):1-25.
6. El Aidy S, van den Bogert B, Kleerebezem M. The small intestine microbiota, nutritional modulation and relevance for health. Curr Opin Biotechnol. 2015;32:14-20.
7. Mani S, Boelsterli UA, Redinbo MR. Understanding and Modulating Mammalian-Microbial Communication for improved Human Health. Annu Rev Pharmacol Toxicol. 2014;54:559-80.
8. Gingell R, Bridges JW, Williams RT. The Role of the Gut Flora in the Metabolism of Prontosil and Neoprontosil in the Rat. Xenobiotica. 1971;1(2):143-56.
9. Prudhviraj G, Vaidya Y, Singh SK, Yadav AK, Kaur P, Gu-lati M, et al. Effect of co-administration of probiotics with polysaccharide based colon targeted delivery systems to optimize site specific drug release. European Journal of Phar-maceutics and Biopharmaceutics. 2015;97, Part A:164-72.
10. Peppercorn MA, Goldman P. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine. J Pharmacol Exp Ther. 1972;181(3):555-62.
11. Mikov M, Lee HJ, Fawcett JP. The influence of probiotic treatment on sulfasalazine metabolism in rat gut contents. Asian J Pharmacokinet Pharmacodynam. 2006;6:337-42.
12. Yoo DH, Kim iS, Van Le TK, Jung iH, Yoo HH, Kim DH. Gut microbiota-mediated drug interactions between lovas-tatin and antibiotics. Drug Metab Dispos. 2014;42(9):1508-13.
13. Matuskova Z, Anzenbacherova E, Vecera R, Tlaskalova-Hogenova H, Kolar M, Anzenbacher P. Administration of a probiotic can change drug pharmacokinetics: effect of E. coli Nissle 1917 on amidarone absorption in rats. PloS One. 2014;9(2):e87150.
14. Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, et al. Alleviating Cancer Drug Toxicity by inhibiting a Bacterial Enzyme. Science. 2010;330(6005):831-5.
15. Kehrer DFS, Sparreboom A, Verweij J, de Bruijn P, Nierop CA, van de Schraaf J, et al. Modulation of irinotecan-in-duced Diarrhea by Cotreatment with Neomycin in Cancer Patients. Clin Cancer Res. 2001;7(5):1136-41.
16. Saitta KS, Zhang C, Lee KK, Fujimoto K, Redinbo MR, Boelsterli UA. Bacterial β-glucuronidase inhibition protects mice against enteropathy induced by indomethacin, keto-profen or diclofenac: mode of action and pharmacokinetics. Xenobiotica. 2014;44(1):28-35.
17. Liang X, Bittinger K, Li X, Abernethy DR, Bushman FD. Bidirectional interactions between indomethacin and the murine intestinal microbiota. Elife. 2015;4:e08973.
18. Saha JR, Butler V, Neu H, Lindenbaum J. Digoxin-inacti-vating bacteria: identification in human gut flora. Science. 1983;220(4594):325-7.
19. Haiser HJ, Gootenberg DB, Chatman K, Sirasani G, Balskus EP, Turnbaugh PJ. Predicting and Manipulating Cardiac Drug inactivation by the Human Gut Bacterium Eggerthella lenta. Science. 2013;341(6143):295-8.
20. Lindenbaum J, Rund DG, Butler VPJ, Tse-Eng D, Saha JR. inactivation of Digoxin by the Gut Flora: Reversal by Antibiotic Therapy. N Engl J Med. 1981;305(14):789-94.
21. Clayton TA, Baker D, Lindon JC, Everett JR, Nicholson JK. Pharmacometabonomic identification of a significant host-microbiome metabolic interaction affecting human drug metabolism. Proc Natl Acad Sci U S A. 2009;106(34):14728-33.
22. Sivan A, Corrales L, Hubert N, Williams JB, Aquino-Michaels K, Earley ZM, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science. 2015;350(6264):1084-9.
23. Viaud S, Saccheri F, Mignot G, Yamazaki T, Daillere R, Hannani D, et al. The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide. Science. 2013;342(6161):971-6.
24. Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science. 2015;350(6264):1079-84.
25. Lehouritis P, Cummins J, Stanton M, Murphy CT, McCarthy FO, Reid G, et al. Local bacteria affect the efficacy of chemotherapeutic drugs. Sci Rep. 2015;5:14554.
26. Davidson MH, Toth PP. Comparative effects of lipid-lower-ing therapies. Prog Cardiovasc Dis. 2004;47(2):73-104.
27. Postmus i, Trompet S, Deshmukh HA, Barnes MR, Li X, Warren HR, et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun. 2014;5.
28. Mangravite LM, Thorn CF, Krauss RM. Clinical implications of pharmacogenomics of statin treatment. Pharmacogenomics J. 2006;6(6):360-74.
29. Kaddurah-Daouk R, Baillie RA, Zhu H, Zeng ZB, Wiest MM, Nguyen UT, et al. Enteric microbiome metabolites correlate with response to simvastatin treatment. PloS One. 2011;6(10):e25482.
30. Lye HS, Rusul G, Liong MT. Removal of cholesterol by lactobacilli via incorporation and conversion to coprostanol. J Dairy Sci. 2010;93(4):1383-92.
31. Albaugh VL, Judson JG, She P, Lang CH, Maresca KP, Joyal JL, et al. Olanzapine promotes fat accumulation in male rats by decreasing physical activity, repartitioning energy and increasing adipose tissue lipogenesis while impairing lipolysis. Mol Psychiatry. 2011;16(5):569-81.
32. Davey KJ, Cotter PD, O'Sullivan O, Crispie F, Dinan TG, Cryan JF, et al. Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat. Transl Psychiatry. 2013;3:e309.
33. Turnbaugh PJ, Hamady M, Yatsunenko T, Cantarel BL, Duncan A, Ley RE, et al. A core gut microbiome in obese and lean twins. Nature. 2009;457(7228):480-4.
34. Davey KJ, O'Mahony SM, Schellekens H, O'Sullivan O, Bi-enenstock J, Cotter PD, et al. Gender-dependent consequences of chronic olanzapine in the rat: effects on body weight, inflammatory, metabolic and microbiota parameters. Psychopharmacology. 2012;221(1):155-69.
35. Goldin BR, Peppercorn MA, Goldman P. Contributions of host and intestinal microflora in the metabolism of L-dopa by the rat. J Pharmacol Exp Ther. 1973;186(1):160-6.
36. Hashim H, Azmin S, Razlan H, Yahya NW, Tan HJ, Manaf MR, et al. Eradication of Helicobacter pylori infection improves levodopa action, clinical symptoms and quality of life in patients with Parkinson's disease. PloS One. 2014;9(11):e112330.
37. Pierantozzi M, Pietroiusti A, Galante A, Sancesario G, Lunardi G, Fedele E, et al. Helicobacter pylori-induced reduction of acute levodopa absorption in parkinson's disease patients. Ann Neurol. 2001;50(5):686-7.
38. Pierantozzi M, Pietroiusti A, Brusa L, Galati S, Stefani A, Lunardi G, et al. Helicobacter pylori eradication and l-dopa absorption in patients with PD and motor fluctuations. Neurology. 2006;66(12):1824-9.
39. Lee WY, Yoon WT, Shin HY, Jeon SH, Rhee P-L. Helicobacter pylori infection and motor fluctuations in patients with Parkinson's disease. Mov Disord. 2008;23(12):1696-700.
40. Venkataramanan R, Swaminathan A, Prasad T, Jain A, Zuck-erman S, Warty V, et al. Clinical pharmacokinetics of tacrolimus. Clin Pharmacokinet. 1995;29(6):404-30.
41. Lee JR, Muthukumar T, Dadhania D, Taur Y, Jenq RR, Toussaint NC, et al. Gut Microbiota and Tacrolimus Dosing in Kidney Transplantation. PloS One. 2015;10(3):e012239.
42. Tozaki H, Emi Y, Horisaka E, Fujita T, Yamamoto A, Mu-ranishi S. Degradation of insulin and calcitonin and their protection by various protease inhibitors in rat caecal contents: implications in peptide delivery to the colon. J Pharm Pharmacol. 1997;49(2):164-8.
43. Lavrijsen K, van Dyck D, van Houdt J, Hendrickx J, Mon-baliu J, Woestenborghs R, et al. Reduction of the prodrug loperamide oxide to its active drug loperamide in the gut of rats, dogs, and humans. Drug Metab Dispos. 1995;23(3):354-62.
44. Koch RL, Goldman P. The anaerobic metabolism of metron-idazole forms N-(2-hydroxyethyl)-oxamic acid. J Pharmacol Exp Ther. 1979;208(3):406-10.
45. Takeno S, Sakai T. involvement of the intestinal microflora in nitrazepam-induced teratogenicity in rats and its relationship to nitroreduction. Teratology. 1991;44(2):209-14.
46. Basit AW, Newton JM, Lacey LF. Susceptibility of the H2-receptor antagonists cimetidine, famotidine and nizatidine, to metabolism by the gastrointestinal microflora. int J Pharm. 2002;237(1–2):23-33.
47. Wadworth AN, Fitton A. Olsalazine. A review of its phar-macodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs. 1991;41(4):647-64.
48. Meuldermans W, Hendrickx J, Mannens G, Lavrijsen K, Janssen C, Bracke J, et al. The metabolism and excretion of risperidone after oral administration in rats and dogs. Drug Metab Dispos. 1994;22(1):129-38.
49. Kitamura S, Sugihara K, Kuwasako M, Tatsumi K. The role of mammalian intestinal bacteria in the reductive metabolism of zonisamide. J Pharm Pharmacol. 1997;49(3):253-6.